Global Biobanking Market

Biobanking Market Size, Share, Growth Analysis, By Type(Population-based Biobanks, Disease-based Biobanks, Academic Biobanks, Hospital-based Biobanks), By Sample(Blood Products, Cell Lines, Nucleic Acids, Human Tissues), By Application(Drug Discovery, Genomic Research, Personalized Medicine, Regenerative Medicine), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2200 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 98 | Figures: 76

Biobanking Market Regional Insights

North America plays an important role in the global biobanking market, driven by advanced healthcare infrastructure, strong research capabilities and an increasing emphasis on innovation in medical research and personalized medicine. North America is hub to many of the world’s leading research institutes, universities, and biopharmaceutical companies. These organizations actively participate in biobanking initiatives to support cutting-edge research in genomics, oncology, and personalized medicine. Collaboration between academic institutions and industry stakeholders supports innovation and accelerates the discovery of new treatments, making this area a hub for biobanking activities. 

Asia-Pacific is expected to exhibit the fastest CAGR during the forecast period. The growth can be attributed to investments in developing countries such as India, China and Japan. These countries have been actively engaged in biobanking market development with several business initiatives to strengthen their market position. For example, in November 2023, AIG Hospital launched its first biobank in the southern region of India. The biobank collected more than 100,000 tissue and blood samples over the next decade. Private biobanks in India are spurring biobanking in the country. For example, biobanks such as International Institute for Innovation and Technology Biorepository (i3tBR), JIPMER PBMC Puducherry, MCRI, and National Liver Disease Biobank represent the state-of-the-art biobanks in the country. The Australian Biobank promotes accredited research activities and is funded by the Australian Department of Health. There are also many other biobanks in the country, including the Australian Breast Cancer Tissue Bank, the Department of Human Studies. Additionally, biobank, the country has taken a lot of initiatives to create large scale population-based biobanks.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Biobanking Market size was valued at USD 69.5 billion in 2022 and is poised to grow from USD 72 billion in 2023 to USD 95.5 billion by 2031, growing at a CAGR of 6.8% in the forecast period (2024-2031).

The competitive environment of the Biobanking market is dynamic and characterized by the presence of several key players engaging in strategic initiatives to solidify their market position. Established companies often focus on expanding their service offerings, investing in advanced technologies, and forming partnerships with research institutions and pharmaceutical companies. Additionally, mergers and acquisitions play a role in enhancing capabilities and extending geographic reach. The market's dynamism is further fueled by the entry of new players, particularly in emerging regions, contributing to increased competition. 'AMS Biotechnology (Europe) Ltd.', 'ASKION GmbH', 'Avantor, Inc.', 'Azenta, Inc. (Azenta)', 'Bay Biosciences LLC', 'BioIVT & Elevating Science', 'Boca Biolistics', 'CTI Biotech', 'Cureline Inc.', 'Firalis SA', 'Geneticist Inc.', 'Hamilton Bonaduz AG', 'Isenet Biobanking', 'Merck & Co., Inc.', 'ProteoGenex Inc.', 'Qiagen NV', 'Stemcell Holdings, Inc.', 'STEMCELL Technologies Inc.', 'Thermo Fisher Scientific Inc.', 'US Biolab Corp. Inc.'

A key driver of the biobanking market is the rapid growth in genomics research and personalized medicine. As the understanding of genetic markers and disease progression increases, the demand for biobanks storing high-quality biosamples for genomic analysis increases. These biosamples are essential for researchers to develop targeted therapies so is personalized medicine, making biobanking central to the future of healthcare. 

Integrating Artificial Intelligence (AI) and Big Data Analytics: One of the most important trends in the biobanking market is the integration of artificial intelligence (AI) and big data analytics. This technology helps biobanks optimize specimen tracking, improve data management, and improve the quality of specimen storage. AI-driven analytics enable researchers to identify patterns and insights from large biosample datasets, facilitating the discovery of the new biomarkers and accelerating drug development processes. 

North America plays an important role in the global biobanking market, driven by advanced healthcare infrastructure, strong research capabilities and an increasing emphasis on innovation in medical research and personalized medicine. North America is hub to many of the world’s leading research institutes, universities, and biopharmaceutical companies. These organizations actively participate in biobanking initiatives to support cutting-edge research in genomics, oncology, and personalized medicine. Collaboration between academic institutions and industry stakeholders supports innovation and accelerates the discovery of new treatments, making this area a hub for biobanking activities. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Biobanking Market

Report ID: SQMIG35H2200

$5,300
BUY NOW GET FREE SAMPLE